19.03.2021: What tools do National health systems have at their disposal to further reward the development and uptake of much needed new antibiotics and diagnostics? Undertaken by the team at the Austrian Institute of Public Health (GÖG), the Global AMR R&D Hub is happy to publicly-release this important study today. This comprehensive review of available policy tools within pricing, reimbursement and procurement in ten G20 countries, includes concrete examples and suggestions for learning, leverage and implementation. This is one of three studies that were used to derive our recently-published recommendations put forward to the G7 and G20 for their ongoing reflections. Download the full report here and the accompanying policy brief here.
24.06.2024
UICC Virtual Dialogue on AMR & Cancer
How can R&D for novel antimicrobial medicines and a secure access pipeline effectively address AMR? On 24th June, Dr. Lesley Ogilvie, the Hub Secretariat Director took part in the Virtual Dialogue: “Addressing Antimicrobial Resistance for Better Cancer Care – The Important Role of R&D”.